Altamira Therapeutics Obtains Extended ISO 13485 Quality Management System Certification For Bentrio Nasal Spray
Portfolio Pulse from Benzinga Newsdesk
Altamira Therapeutics has received an extended ISO 13485 certification for its Bentrio nasal spray, indicating compliance with international quality management standards for medical devices.
September 27, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Altamira Therapeutics, trading under the symbol CYTO, has obtained an extended ISO 13485 certification for its Bentrio nasal spray. This certification enhances the company's credibility and may positively impact its market position.
The extended ISO 13485 certification is a significant achievement for Altamira Therapeutics, as it demonstrates compliance with international quality standards. This can enhance the company's reputation and potentially lead to increased sales and partnerships, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100